proteomic changes upon treatment with semaglutide in individuals with obesity effects of short-term liraglutide vs. placebo a blinded crossover RCT: Implications for efficacy, safety, and comparison Super interesting Novo Nordisk Nature

Conventional disease-modifying antirheumatic drugs (DMARDs) also influence ferroptosis pathways

CKD is predicted to be the fifth largest cause of mortality by 2040 and so slowing progression of CKD and reducing cardiovascular mortality will reduce NHS spend and is hugely important for patients, Clare Morlidge, a consultant renal pharmacist and deputy chair of the UK Renal Pharmacy Group, tells The Pharmaceutical Journal , adding that semaglutide is another medication in the cupboard for slowing the progression of CKD

Your journey can continue even if the medication is stopped

The number of drinks a person has, along with their weight and sex, can affect their BAC levels